Key result
VKA use linked to ~6% annual increase in aortic valve calcification score, unlike NOACs.
Why the study?
Vitamin K antagonists are suspected of causing aortic valve calcification, but whether treated patients have increased calcification scores compared to those receiving NOACs or no anticoagulation remained unclear.
Does Vitamin K antagonist treatment increase aortic valve calcification compared to NOACs or no treatment in a population-based cohort?
Observational (n=14,604)
Does Vitamin K antagonist treatment increase aortic valve calcification compared to NOACs or no treatment in a population-based cohort?
Effect estimate: REC 1.06 (95% CI 1.02-1.10)
VKA use is associated with a duration-dependent increase in aortic valve calcification compared to non-use, an association not seen with NOACs.
Authors
No takes yet. Share an insight, caveat, or question.
May support preferring NOACs to limit aortic valve calcification risk; hypothesis-generating and requires randomized confirmation.
Sønderskov et al. (2020) conducted an observational in Aortic valve calcification (n=14,604). Vitamin K antagonists (VKAs) vs. New oral anticoagulants (NOACs) and no anticoagulant treatment was evaluated on Aortic valve calcification (AVC) score (REC 1.06, 95% CI 1.02-1.10). Vitamin K antagonist use was associated with a 6% average increase in aortic valve calcification score per year of treatment compared to non-use (REC 1.06; 95% CI 1.02-1.10), unlike NOACs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: